rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cogent Biosciences, Inc.

COGT · Nasdaq

Health CareBiotechnologyNot moving yet

COGT stood above a rising 150-day average in 36 of the last 52 weekly readings, and has been out of that trend for the last 9 weeks. It is 16.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 9
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$755.6M
Officials’ trades on record
1
Institutions holding
307 (+16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 36 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$466.9M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Chris Jacobs House: U.S. House ClerkNY27bought$1k–$15k12 Dec 2022filed 20 Jan 2023

Insiders

Buy orders, 12 months0
Sale orders, 12 months7
Buyers · sellers0 · 6
WhoDidSharesTraded
Arlene MorrisDirectorsold42,349at $37.0927 Aug 2026filed 31 Aug 2026
Arlene MorrisDirectorsold3,161at $37.5427 Aug 2026filed 31 Aug 2026
Fairmount Funds Management LlcDirectorsold7,000,000at $34.6631 Mar 2026filed 31 Mar 2026
Fairmount Funds Management LlcDirectorsold3,500,000at $36.4022 Jan 2026filed 22 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders307+16 on the quarter
New · exited64 · 47
Reported value$7.2B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 202625,681,174$993.9M+2,558,426+11.1%
BlackRock, Inc.added · filed 7 Aug 202617,352,646$671.5M+1,307,632+8.1%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20268,072,411$312.4M+739,078+10.1%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,412,330$286.9M+517,371+7.5%
STATE STREET CORPadded · filed 7 Aug 20266,964,919$269.5M+1,301,376+23.0%
Jupiter Topco LLCnew · filed 14 Aug 20266,624,848$256.4M+6,624,848
Fairmount Funds Management LLCunchanged · filed 14 Aug 20265,503,418$213.0M00.0%
DEERFIELD MANAGEMENT COMPANY, L.P.reduced · filed 14 Aug 20265,006,104$193.7M-4,037,799−44.6%
TCG Crossover Management, LLCreduced · filed 14 Aug 20264,854,436$187.9M-92,458−1.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,508,998$174.5M+809,479+21.9%
31 Mar 2023 – 30 Jun 2026
117209300Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Karen Jean Ferrante Company insiderDirector · last 1 Oct 20260 · 0
Arlene Morris Company insiderDirector · last 27 Aug 20260 · 1
Christopher W. Cain Company insiderDirector · last 9 Jun 20260 · 0
Matthew Ros Company insiderDirector · last 9 Jun 20260 · 0
Peter Evan Harwin Company insiderDirector · last 9 Jun 20260 · 0
Todd Shegog Company insiderDirector · last 9 Jun 20260 · 0
Andrew R. Robbins Company insiderPresident and CEO · last 19 May 20260 · 0
Fairmount Funds Management LLC Company insiderDirector · last 31 Mar 20263 · 2
Evan Kearns Company insiderChief Legal Officer · last 26 Dec 20250 · 1
Jessica Sachs Company insiderChief Medical Officer · last 26 Dec 20250 · 1
John Edward Robinson Company insiderChief Scientific Officer · last 26 Dec 20250 · 1
John L. Green Company insiderChief Financial Officer · last 26 Dec 20250 · 2

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-38.2%
Debt to equityFY 2025 · to 31 Dec 20250.35×
Share count trendFY 2025 · to 13 Feb 20260.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$312.0M
Free cash flowFY 2025 · to 31 Dec 2025−$266.0M

Analyst forecasts

No analyst forecasts yet.